帝斯曼和Amyris宣布，帝斯曼将收购Amyris巴西工厂，进一步增强二者的战略联盟合作。Amyris巴西工厂及其法尼烯产品相关知识产权估值在5800万美元，除此之外，还包含三年的价值回报约3750万美元（即前期预付约9600万美元）。帝斯曼会继续执行同Amyris或其他相关方的供货协议。帝斯曼会协助Amyris在巴西投建第二座生产工厂。根据惯例，该交易预计在未来几个月内结束。
原文如下：
DSM Expands Strategic Alliance with Amyris and Acquires Brazilian Production Facility from Amyris
Royal DSM (AEX: DSM.AS), a global science-based company active in health, nutrition and materials and Amyris, Inc. (Nasdaq: AMRS), the industrial bioscience company, today announced that they have enhanced their strategic alliance through the sale of Amyris Brasil Ltda to DSM and the establishment of a long-term manufacturing partnership for Amyris’ high-volume products.
The consideration for Amyris Brasil Ltda (which owns and operates the Brotas 1 production facility) and intellectual property related to farnesene (a bio-based key intermediate for many applications) is US$ 58 million plus an additional value share arrangement over a three-year period amounting to US$ 37.5 million (aggregate upfront consideration of US$ 96 million). In addition to the consideration upfront, there is potential for a future value share in line with Amyris’ business model.
DSM will continue existing supply-agreements to Amyris and other parties. DSM will also supply Amyris with specialty compounds until it realizes its Brotas 2 specialties production facility. Amyris is accelerating the construction of its second facility dedicated to specialty products while maintaining the manufacturing process development and business support capability located in Campinas, Brazil.
Subject to customary conditions, the transaction is expected to close in the next few months.
With the acquisition of the Brotas 1 facility, DSM adds a state-of-the-art biotechnology-based production site in Brazil to its global network, with abundant availability of sustainable raw materials (sugar cane), securing production capacity for its rich pipeline of sustainable and bio-based solutions. Having broad experience in operating large-scale fermentation plants, DSM will optimize the operational performance of the site.
The strategic alliance between DSM and Amyris started in May 2017 with an equity investment by DSM in Amyris, and has since been expanded with several significant product development collaborations.
The sale of the Brotas 1 facility, which was designed to produce high volumes of farnesene, together with the creation of a long-term production relationship for high-volume farnesene-based intermediates will enable Amyris to focus on its core strength of developing breakthrough bioscience technologies through a portfolio approach that continues to target key markets, as well as the production of specialty products.
“Following our equity investment in Amyris and subsequent product development cooperations, I am pleased that we can add a state-of-the-art fermentation-based production facility to our network. Our know-how in fermentation, downstream process development and large-scale manufacturing will allow us to further improve the operational performance of the facility while further strengthening our strategic alliance with Amyris”, said Chris Goppelsroeder, President & CEO of DSM Nutritional Products.
“We are very pleased with the continued expansion of our strategic alliance with DSM,” said John Melo, Amyris President & CEO. “This manufacturing partnership and the sale of our Brotas 1 factory allows us to accelerate the development and manufacturing of specialty, high-performance ingredients. We are building a specialty plant at Brotas (Brotas 2) and also expect to complete our São Martinho plant to focus on sweeteners. The combination of these actions provides us the manufacturing footprint to meet our current demand through the next 3-5 years and to manage this within our funding constraints.”
Continued Melo, “This transaction completes a planned shift from operating a plant originally designed to produce high volumes of farnesene, to producing an expanding number of high-value, specialty ingredients. This shift will allow Amyris to improve returns and cash flows in order to continue to provide sustainable growth for Amyris and its partners.”
因产能过剩，丹麦皇冠关闭一家主要
菲总统：预计6-7月开售越南产非瘟疫
3月中国大豆进口总量为554万吨，创
3月中国进口猪肉20万吨，同比下降20.6%
非瘟口服疫苗？欧盟启动新的非瘟疫
脚下有泥，心中有光 | 牧原农艺师
携手共赢，友谊长存：江西正邦作物保
国新办举行7月份国民经济运行情况新
农业农村部就2022年“三夏”生产形势